<
https://www.independent.co.uk/news/health/covid-vaccine-mrna-cancer-treatment-study-b2849208.html>
"Scientists have discovered a powerful and unexpected new ally in the fight
against cancer: the Covid mRNA vaccine.
Patients battling advanced lung or skin cancer who received a Covid mRNA jab
within 100 days of starting immunotherapy lived significantly longer than those
who didn’t, according to groundbreaking research by teams in the US.
The researchers said the discovery could mark a pivotal moment in over a decade
of research into mRNA-based treatments designed to awaken the immune system
against cancer – and could be a “significant step” toward the elusive goal of a
universal cancer vaccine.
The findings are based on analysis of more than 1,000 patients’ records,
carried out by the University of Florida and the University of Texas MD
Anderson Cancer Center, where the patients were being treated.
The current results are preliminary, the teams said, but if validated in a
randomised clinical trial now in design, the study “could have a widespread
clinical impact”.
“The implications are extraordinary. This could revolutionise the entire field
of oncologic care,” said senior researcher Dr Elias Sayour, a paediatric
oncologist at the University of Florida.
“We could design an even better nonspecific vaccine to mobilise and reset the
immune response, in a way that could essentially be a universal, off-the-shelf
cancer vaccine for all cancer patients.”
The study involved records of 180 advanced lung cancer patients who received a
Covid vaccine within a 100-day period before or after starting immunotherapy
drugs. Meanwhile, 704 people were treated with the same drugs who did not
receive the vaccine. Getting the vaccine was associated with a near doubling of
median survival, from 20.6 months to 37.3 months.
Similarly, among metastatic melanoma patients – those with cancer that has
spread from its original location, typically the skin, to other parts of the
body – 43 of them received a vaccine within 100 days of initiating
immunotherapy, while 167 patients did not receive a vaccine. With the vaccine,
median survival increased from 26.7 months to a range of 30 to 40 months, the
researchers found. At the time the data were collected, some patients were
still alive, meaning the vaccine effect could be even stronger.
Receiving non-mRNA pneumonia or flu vaccines resulted in no changes in
longevity, the team said."
Via Violet Blue’s
Threat Model - Covid: October 23, 2025
https://www.patreon.com/posts/covid-october-23-141840402
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
